Skip to main content
Premium Trial:

Request an Annual Quote

ASU, Pfizer Partner on $5M Type 2 Diabetes Biomarker Project

NEW YORK (GenomeWeb News) – Arizona State University's Biodesign Institute will lead a study with partners at Pfizer, the Phoenix VA Healthcare System, and the University of Arizona's BIO5 Institute aimed at discovering protein biomarkers to predict cardiovascular disease in people with type 2 diabetes.

The $5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases will fund research using protein sequencing to identify diabetes biomarkers and their functional states and to measure the quantity of particular proteins.

"The envisioned biomarkers will better predict the onset of cardiovascular disease in the context of type 2 diabetes and help define the optimal therapeutic or pharmaceutical interventions to significantly improve patient outcomes," principal investigator Randy Nelson, director of the Molecular Biosignatures Analysis Unit at the Biodesign Institute, said in a statement.

The grant was awarded under an NIDDK program aimed at creating collaborative interdisciplinary team science projects in diabetes, endocrinology, and metabolic diseases that have the potential to advance clinical research.

"Identifying markers to predict heart and blood vessel diseases in people with type 2 diabetes is challenging but important," added Salvatore Sechi, director of NIDDK's Proteomic Program and Diabetes Systems Biology Program. "We are looking to the project's team of experts in proteomics, drug development, biostatistics, and clinical studies to advance the difficult search for markers that may be useful for both diagnosis and for assessing potential new drug therapies."

The partners will study and validate markers in people with diabetes, some of whom have had a heart attack, with the long-term goal of generating enough markers to create panels that can predict risk and identify drug targets.

Pfizer's Personalized Medicine branch will be involved in translating the prognostic biomarkers of cardiovascular disease risk for use in decision-making during type 2 diabetes drug development process.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.